Balancing Molecular Size, Activity, Permeability, and Other Properties: Drug Candidates in the Context of Their Chemical Structure Optimization.


Journal

Journal of chemical information and modeling
ISSN: 1549-960X
Titre abrégé: J Chem Inf Model
Pays: United States
ID NLM: 101230060

Informations de publication

Date de publication:
13 Aug 2024
Historique:
medline: 13 8 2024
pubmed: 13 8 2024
entrez: 13 8 2024
Statut: aheadofprint

Résumé

Chemical structure optimization is a vital part of early drug discovery projects. Starting with compounds that show activity on the target of interest, the chemical structures are subsequently optimized toward a development candidate (DC) molecule with the best chances of clinical success. However, the DCs in the context of such optimization programs, as well as detailed characterization of major limiting factors, have not been investigated in detail so far. Here, we report an analysis of the historical DC molecules at Novartis since 2005 in the context of their optimization projects. Mapping the DCs into their respective chemical optimization series, we find that these tend to be synthesized rather early in a substantial number of cases. Further analysis of structural properties, ADMET, and potency-related readouts revealed that DC compounds tend to be generally significantly smaller, more permeable, and have higher ligand efficiency than other compounds sent to

Identifiants

pubmed: 39137447
doi: 10.1021/acs.jcim.4c00898
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Maximilian Beckers (M)

Biomedical Research, Novartis Pharma AG, Postfach, Basel 4002, Switzerland.

Finton Sirockin (F)

Biomedical Research, Novartis Pharma AG, Postfach, Basel 4002, Switzerland.

Nikolas Fechner (N)

Biomedical Research, Novartis Pharma AG, Postfach, Basel 4002, Switzerland.

Nikolaus Stiefl (N)

Biomedical Research, Novartis Pharma AG, Postfach, Basel 4002, Switzerland.

Classifications MeSH